Typewriter Therapeutics

CIK 0002156390 · Biotech · Private

All-RNA gene writing platform for therapeutic gene modification

typewritertx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$56M
1 Form D · Sep 2026
1 months since last filing
Contracts
—
No federal contracts on record
Patents
7
0 granted · 7 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$56,299,999
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
15423HELIX INC—$12M
1543Adcytherix——
1544WALIA, RAMPYARI——
1545Typewriter Therapeutics—$56M
1546FORTISCIENCE, INC.——
1547WOODLAND PHARMACEUTICALS, LLC——
1548Bohemica Pharmaceuticals, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 7
  • Repeat Dosing Of Retrotransposonsapplication
  • New R2 Retrotransposons For Gene Writingapplication
  • R2 Retrotransposons For Gene Writingapplication
  • Repeat Dosing Of Retrotransposonsapplication
  • New R2 Retrotransposons For Gene Writingapplication
  • New R2 Retrotransposons For Gene Writingapplication
  • R2 Retrotransposons For Gene Writingapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.